ArticleJournal of the American Heart Association2026
Association Between Nerve Growth Factor and Clinical Stroke and Covert Brain Infarcts: The FHS.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNerve growth factor (NGF) is associated with neuroprotection and neural repair. However, whether NGF is associated with future stroke in humans is unknown. We determined the association between late midlife serum NGF and subsequent risk of clinical stroke, covert brain infarcts, and white matter hyperintensity volume on magnetic resonance imaging.
methodsA total of 1709 stroke-free participants from the FHS (Framingham Heart Study) Offspring and Omni 1 cohorts who attended Offspring examination 7/Omni 1 examination 2, respectively (1998-2001), with baseline serum NGF were included. The primary outcomes were incident all-cause and ischemic stroke. Secondary outcomes included covert brain infarct and white matter hyperintensity volume on magnetic resonance imaging. Serum NGF was analyzed continuously and by tertiles, adjusting for age, sex, and vascular risk factors. Cox proportional hazards regression models were used to assess the association between serum NGF and all-cause and ischemic stroke risk. Linear and logistic regression models were used to evaluate the association between serum NGF levels and white matter hyperintensity volume and covert brain infarct.
resultsMean age was 60.6±9.6 years, and 47.6% were men. The median follow-up for incident stroke was 19.2 (interquartile range, 14.7-21.3) years. The highest tertile (tertile 3) of NGF, compared with the bottom tertile (tertile 1), was associated with a reduced risk of incident all-cause stroke (hazard ratio [HR], 0.59 [95% CI, 0.37-0.94];
conclusionsHigher serum NGF in late midlife demonstrates a protective association with future risk of silent and clinically overt stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.